Journals / Klinik Psikofarmakoloji Bülteni / 2011 / Cilt: 21 - Sayı: 3

Ziprasidon ve tardif distoni: Bir olgu sunumu ve literatürün gözden geçirilmesi

Ziprasidone and tardive dystonia: A case report and literature review

Pages
242–245
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although atypical antipsychotic drugs cause fewer extrapyramidal side effects than typical antipsychotics, we must be cautious when prescribing these drugs because of their disabling side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 40-year-old woman with the diagnosis of schizoaffective disorder had been treated with different typical and atypical antipsychotic drugs since the age of 26.
📊
Key Findings & Data:Discontinuation of ziprasidone produced no benefit; thus clozapine, 75 mg/day, was initiated both for psychotic symptoms and dystonia.
💡
Conclusion & Impact:Although atypical antipsychotic drugs cause fewer extrapyramidal side effects than typical antipsychotics, we must be cautious when prescribing these drugs because of their disabling side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 40-year-old woman with the diagnosis of schizoaffective disorder had been treated with different typical and atypical antipsychotic drugs since the age of 26. Three months after self-discontinuing her medication, she experienced an exacerbation of her psychotic symptoms, so ziprasidone and valproic acid treatment were started. Six months after initiation of the treatment, tardive dystonia was developed involving the neck region. Discontinuation of ziprasidone produced no benefit; thus clozapine, 75 mg/day, was initiated both for psychotic symptoms and dystonia. Due to lack of improvement in the dystonia and because she suffered from side effects, the dosage of clozapine was decreased to 25 mg/day and botulinum toxin type A treatment was administered. She had partial improvement and repeated injections were planned. Although atypical antipsychotic drugs cause fewer extrapyramidal side effects than typical antipsychotics, we must be cautious when prescribing these drugs because of their disabling side effects.

Özet

Şizoafektif bozukluk tanısı alan 40 yaşındaki kadın hasta, 26 yaşından itibaren farklı tipik ve atipik antipsikotik ilaçlar ile izlenmiştir. Tedavisini kendi isteği ile kesen hastanın 3 ay sonra psikotik semptomlarında alevlenme olması üzerine ziprasidon ve valproik asit tedavisi başlanmıştır. Tedavinin 6. ayında servikal bölgede tardif distoni gelişmesi üzerine hastanın ziprasidon tedavisi kesildi, ancak yakınmaları devam etti. Distonik yakınmaları ve psikotik semptomları göz önünde bulundurularak 75 mg/gün klozapin tedavisi başlandı ancak yanıt alınamadı. Semptomlarda düzelme sağlanamaması ve hastanın yan etkilerden yakınması üzerine, klozapin dozu 25 mg/güne düşüldü ve botilinum toksini tip A uygulandı. Kısmi düzelme sağlanması üzerine botilinum enjeksiyonların tekrarı planlandı. Atipik antipsikotik ilaçların ekstrapiramidal yan etkileri tipik antipsikotiklerden daha az olsa da, kısıtlayıcı olabilen bu tür yan etkileri nedeniyle dikkatli olunmalıdır.

🔖

Cite This Article

SARANDÖL, A., EKER, S. S., AKKAYA, C., TURAN, A. B., KARLI, N. (2022). Ziprasidon ve tardif distoni: Bir olgu sunumu ve literatürün gözden geçirilmesi. Klinik Psikofarmakoloji Bülteni, Cilt: 21 - Sayı: 3, 242–245. https://ajindex.com/articles/574187

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275(1):101-13
  2. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425(3):197-201
  3. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002;36(5):839-51
  4. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007;13(2):137-77
  5. Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med 2007;74(8):597-606
  6. Agarwal PA, Ichaporia NR. Flupenthixol-induced tardive dystonia presenting as severe dysphagia. Neurol India 2010;58(5):784-5
  7. Aggarwal A, Jiloha RC. Olanzapine induced tardive dystonia. Indian J Pharmacol 2008;40(5):237-8
  8. Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J Neuropsychiatry Clin Neurosci 2007;19(1):86-7
  9. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124(1-2):188-96
  10. Stahl SM, Davis KL, Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. J Clin Psychopharmacol 1982;2(5):321-8
  11. Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone. Am J Psychiatry 2005; 162(11): 2191
  12. Tibrewal P, Zutshi A, Math SB. Tardive dystonia and ziprasidone: a case report. Prim Care Companion J Clin Psychiatry 2008;10(1):71- 2
  13. Tsai CS, Lee Y, Chang YY, Lin PY. Ziprasidone-induced tardive laryngeal dystonia: a case report. Gen Hosp Psychiatry 2008;30(3):277-9
  14. Kutlu A, Dündar S, Altun NS, Budak F. Ziprasidone induced tardive cervical dystonia. Psychopharmacology Bulletin 2009 42(4): 64-8
  15. Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998;19(1): 57-72
  16. Brans JW, Lindeboom R, Snoek JW. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46 (4):1066-72
  17. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75(7):951-7
  18. Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, et al. Family his